Cancer and Metastasis Reviews

, Volume 3, Issue 2, pp 99–114

Role of plasma, platelets, and endothelial cells in tumor metastasis

  • Gabriel J. Gasic
Article

Summary

This review studies interactions of tumor cells with a particular host system which is normally responsible for hemostasis and the physiological integrity of the blood vessel luminal surface. With malignancy components of this system are frequently activated, producing abnormalities of blood coagulation, increased platelet responses, and conditions favoring tumor growth and metastasis. Activation of the clotting cascade is mediated by tumor and macrophage procoagulants, acting via Factor X or VII. Thrombin and fibrin are formed. Thrombin also interacts with platelets and the endothelium, potentiating or decreasing coagulation. Generation of thrombin or other tumor mechanisms activate platelets, leading to direct aggregation or secretion of ADP, serotonin, and/or intermediates of the arachidonate metabolism. Vascular lesions caused by tumor attack, platelet secretion, or exogenous agents promoting metastasis may also activate the hemostatic system. It is not yet fully understood how activation of the clotting system, including platelets, contributes to metastasis. Secretion of platelet products appears, however, to be heavily involved. Based on putative mechanisms of action, anticoagulants, platelet inhibitors, thrombocytopenic or vascular repairing agents have been used to control tumor spread. Results depended on the agent and experimental model of metastasis used. Except for coumarin, which was beneficial even against spontaneous metastases, other anticoagulants and platelet inhibitors, excluding perhaps Nafazatrom, gave equivocal results. Thrombocytopenic agents, However, were effective in every tumor system and with any experimental model of metastasis, indicating that platelets play a role in this process. Also consistent were the inhibitory effects of leech salivary gland extract (probably a vascular repairing agent) against lung tumor colonization promoted by ionizing radiation, cyclophosphamide, and cortisone.

Keywords

anticoagulant platelet inhibitors thrombocytopenia leech extract metastasis inhibition mechanism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Semeraro N, Donati MB: Pathways of blood clotting initiation by cancer cells. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 65–82.Google Scholar
  2. 2.
    Slichter SJ, Weiden PL, O'Donnell MR, Storb R: Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors. Blood 59: 1252–1258, 1982.Google Scholar
  3. 3.
    Rickles FR, Edwards RL, Barb C, Cronlund M: Abnormalities of blood coagulation in patients with cancer. Cancer 51: 301–307, 1983.Google Scholar
  4. 4.
    Edwards RL, Rickles FR, Cronlund M: Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation. J Lab Clin Med 98: 917–928, 1981.Google Scholar
  5. 5.
    Lyberg T, Hetland O, Prydz H: Synthesis of thromboplastin protein by a murine macrophage-like cell line. Thromb Haemostas 47: 154–156, 1982.Google Scholar
  6. 6.
    Tracy PB, Rohrbach MS, Mann KG: Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258: 7264–7267, 1983.Google Scholar
  7. 7.
    O'Meara RAQ, Jackson RD: Cytological observations on carcinoma. Ir J Med Sci 391: 327–328, 1958.Google Scholar
  8. 8.
    Gordon SG, Franks JJ, Lewis BJ: Comparison of the procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 62: 773–776, 1979.Google Scholar
  9. 9.
    Boggust WA, O'Brien DJ, O'Meara RAQ, Thornes RD: The coagulative factors of normal human and human cancer tissue. Ir J Med Sci 477: 131–144, 1963.Google Scholar
  10. 10.
    Gordon SG, Franks JJ, Lewis B: Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thrombosis Res 6: 127–137, 1975.Google Scholar
  11. 11.
    Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N: Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 40: 228–233, 1979.Google Scholar
  12. 12.
    Hilgard P, Whur P: Factor X-activating activity from Lewis lung carcinoma. Br J Cancer 41: 642–643, 1980.Google Scholar
  13. 13.
    Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue. Clin Invest 67: 1665–1671, 1981.Google Scholar
  14. 14.
    Gralnick HR: Cancer cell procoagulant activity. Thromb Haemostas 42: 352, 1979.Google Scholar
  15. 15.
    Gralnick HR, Abrell E: Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Hematol 24: 89–99, 1973.Google Scholar
  16. 16.
    Khato J, Suzuki M, Sato H: Quantitative study of thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. Gann 65: 289–294, 1974.Google Scholar
  17. 17.
    Niewiarowski S, Rao AK: Contribution of thrombogenic factors to the pathogenesis of atherosclerosis. Progress in Cardiovascular Diseases 26: 197–222, 1983.Google Scholar
  18. 18.
    Tuszynski GP, Walsh PN, Piperno JR, Koshy A: Association of coagulation factor V with the platelet cytoskeleton. J Biol Chem 257: 4557–4563, 1982.Google Scholar
  19. 19.
    Miletich JP, Jackson CM, Majerus PW: Properties of the factor Xa binding site on human platelets. J Biol Chem 253: 6908–6916, 1978.Google Scholar
  20. 20.
    Detwiler TC: Hypothetical model for the thrombin-platelet interaction. Ann NY Acad Sci 370: 67–71, 1981.Google Scholar
  21. 21.
    Pearlstein E, Ambrogio C, Gasic G, Karpatkin S: Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, Dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide. Cancer Res 41: 4535–4539, 1981.Google Scholar
  22. 22.
    Lollar P, Owen WG: Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium: possible roles in the inactivation of thrombin by antithrombin III. J Clin Invest 66: 1222–1230, 1980.Google Scholar
  23. 23.
    Lollar P, MacIntosh S, Owen WG: Interaction of thrombin with the vascular endothelium in a recirculating Langendorff rabbit heart preparation. Ann NY Acad Sci 401: 234–240, 1982.Google Scholar
  24. 24.
    Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci 78: 2249–2252, 1981.Google Scholar
  25. 25.
    Comp PC, Esmon CT: Activated protein C inhibits platelet prothrombin-converting activity. Blood 54: 1272–1281, 1979.Google Scholar
  26. 26.
    Dahlback B, Stenflo J: Inhibitor effect of activated protein C on activation of prothrombin by platelet-bound factor Xa. J Biochem 107: 331–335, 1980.Google Scholar
  27. 27.
    Gospodarowicz D, Brown KD, Birdwell Cr, Zetter BR: Control of proliferation of human vascular endothelial cells. J Cell Biol 77: 774–788, 1978.Google Scholar
  28. 28.
    Donati MB, Poggi A: Malignancy and haemostasis. Brit J Haemat 44: 173–182, 1980.Google Scholar
  29. 29.
    Hansson GK, Schwartz SM: Evidence for cell death in the vascular endothelium in vivo and in vitro. AJP 112: 278–286, 1983.Google Scholar
  30. 30.
    Gasic GJ, Gasic TB: Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune systems. In: Interaction of platelets and tumor cells. Alan R Liss, New York, 1982, pp 429–444.Google Scholar
  31. 31.
    Holmsen H, Kaplan KL, Dangelmaier CA: Differential energy requirements for platelet responses. Biochem J 208: 9–18, 1982.Google Scholar
  32. 32.
    Paschen W, Patscheke H, Worner P: Aggregation of activated platelets with Walker 256 carcinoma cells. Blut 38: 17–24, 1979.Google Scholar
  33. 33.
    Sloane BF: Lysosomal cathepsin B: correlation with metastatic potential. Science 212: 1151–1153, 1981.Google Scholar
  34. 34.
    Gasic GJ, Koch PAG, Hsk B, Gasic TB, Niewiarowski: Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases. Z Krebsforsch 86: 263–277, 1976.Google Scholar
  35. 35.
    Gasic GJ, Gasic TB, Jimenez SA: Effects of trypsin on the platelet-aggregating activity of mouse tumor cells. Thromb Res 10: 33–45, 1977.Google Scholar
  36. 36.
    Holme R, Oftebro R, Hovig T: In vitro interaction between cultured cells and human blood platelets. Thromb Haemost 40: 89–102, 1978.Google Scholar
  37. 37.
    Jamieson GA, Bastida E, Ordinas A: Mechanisms of platelet aggregation by human tumor cells. In: Jamieson GA (ed) Interaction of platelets and tumor cells. Alan R Liss, New York, 1982, pp 405–413.Google Scholar
  38. 38.
    Hara Y, Steiner M, Baldini MG: Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 40: 1217–1222, 1980.Google Scholar
  39. 39.
    Pearlstein E, Cooper LB, Karpatkin S: Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 93: 332–344, 1979.Google Scholar
  40. 40.
    Karpatkin S, Pearlstein E: Role of platelets in tumor cell metastases. Ann Int Med 95: 636–641, 1981.Google Scholar
  41. 41.
    Lerner WA, Pearlstein E, Ambrogio C, Karpatkin S: New mechanism for tumor-induced platelet aggregation. Comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 31: 463–469, 1983.Google Scholar
  42. 42.
    Bastida E, Ordinas A, Giardina SL, Jamieson GA: Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42: 4348–4352, 1982.Google Scholar
  43. 43.
    Gasic GJ, Boettiger D, Catalfamo JL, Gasic TB, Stewart GJ: Aggregation of platelets and cell membrane vesiculartion by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res 38: 2950–2955, 1978.Google Scholar
  44. 44.
    Gasic GJ, Catalfamo JL, Gasic TB, Avdalovic N: In vitro mechanism of platelet aggregation by purified plasma membrane vesicles shed by mouse 15091A tumor cells. In: Donati MB (ed) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 27–35.Google Scholar
  45. 45.
    Cavanaugh PG, Sloane BF, Bajkowski A, Gasic GJ, Gasic TB, Honn KV: Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin Exp Metastasis 1: 297–307, 1983.Google Scholar
  46. 46.
    Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM: Tumor shedding and coagulation. Science 212: 923–924, 1981.Google Scholar
  47. 47.
    Gasic GJ, Gasic TB, Jimenez SA: Platelet aggregating material in mouse tumor cells: removal and regeneration. Lab Invest 36: 413–419, 1977.Google Scholar
  48. 48.
    Gasic GJ, Gasic TB, Stewart GJ: Mechanisms of platelet aggregation by murine tumor cell sheddings. In: Honn KV, Sloane BF (eds) Hemostatic mechanisms and metastasis. Martinus Nijhoff, Boston, 1984 (in press).Google Scholar
  49. 49.
    Kinlough-Rathbone RL, Packham MA, Reimers HJ, Cazenave JP, Mustard JF: Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23, 187. J Lab Clin Med 90: 707–719, 1977.Google Scholar
  50. 50.
    Feinman RD, Lubowsky J, Charo I, Zabinski MP: The lumiaggregometer: a new instrument for simultaneous messurement of secretion and aggregation by platelets. J Lab Clin Med 90: 125–129, 1977.Google Scholar
  51. 51.
    Warren BA: Platelet-tumor cell interactions: morphological studies. In: de Gaetano G, Garattini S (eds) Platelets: a multidisciplinary approach. Raven Press, New York, 1978, pp 427–446.Google Scholar
  52. 52.
    Ivarsson L: Pulmonary metastasis formation after trauma: an experimental study on the relevance of rheological disturbances of blood. Acta chirurgica scandanavia. Almqvist & Wiksell, Stockholm, Göteborg, 1976.Google Scholar
  53. 53.
    Milas L, Peters LJ: Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. In: Nicolson GL, Milas L (eds) Cancer invasion and metastasis: biologic and therapeutic aspects. Raven Press, New York, 1984, pp 321–336.Google Scholar
  54. 54.
    Van Putten LM, Kram LKJ, van Dierendenck HHC, Smink T, Fuzy M: Enhancement of drugs of metastatic lung nodule formation after intravenous tumor cell injection. Int J Cancer 15: 588–595, 1975.Google Scholar
  55. 55.
    De Brabander M, Aerts F, Borgers M: The influence of a glucocorticoid on the lodgement and development in the lungs of intravenously injected tumor cells. Eur J Cancer 10: 751–755, 1974.Google Scholar
  56. 56.
    Nicolson GL: Cancer metastasis: organ colonization and the cell-surface properties of malignant cells. Biochimica et Biophysica Acta 695: 113–176, 1982.Google Scholar
  57. 57.
    Warren BA: Cancer cell-endothelial reactions: the microinjury hypothesis and localized thrombosis in the formation of micrometastases. In: Donati MB, Davidson JE, Garanttini S (eds) Malignancy and the hemostasis system. Raven Press, New York, 1981, pp 5–26.Google Scholar
  58. 58.
    Gasic GJ, Viner ED, Budzynski AZ, Gasic GP: Inhibition of lung tumor colonization by leech salivary gland extracts from Haementeria ghilianii. Cancer Res 43: 1633–1636, 1983.Google Scholar
  59. 59.
    Murer EH, James HL, Budzynski AZ, Malinconico SM, Gasic GJ: Protease inhibitors in Haementeria leech species. Thrombosis and Haemostasis 51: 24–26, 1984.Google Scholar
  60. 60.
    Gasic GJ, Iwakawa I, Viner C, Viner ED, Milas L: Inhibition of metastasis promotion by cyclophosphamide (CY), cortisone (E) & local thorax irradiation (LTI) by leech salivary gland extract (SGE) from Haementeria officinalis. Proc Am Assoc Cancer Res 25: 58, 1984.Google Scholar
  61. 61.
    Maat B, Hilgard P: Anticoagulants and experimental metastases—evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol 101: 275–283, 1981.Google Scholar
  62. 62.
    Gralnick HR: Cancer cell procoagulant activity. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 57–64.Google Scholar
  63. 63.
    Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB: Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30: 107–112, 1982.Google Scholar
  64. 64.
    Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati MB: Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 57: 733–735, 1981.Google Scholar
  65. 65.
    Zacharski LR: Anticoagulation in the treatment of cancer in man. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 113–128.Google Scholar
  66. 66.
    Hilgard P, Maat B: Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Europ J Cancer 15: 183–187, 1979.Google Scholar
  67. 67.
    Stenflo J: A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. J Biol Chem 251: 355–363, 1976.Google Scholar
  68. 68.
    Hilgard P: Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer 35: 891–893, 1977.Google Scholar
  69. 69.
    Maat B: Selective macrophage inhibition abolishes warfarin-induced reduction of metastases. Br J Cancer 41: 313–316, 1981.Google Scholar
  70. 70.
    Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983.Google Scholar
  71. 71.
    Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S: Platelet-tumor-cell interactions in mice: the role of platelets in the spread of malignant disease. Int J Cancer 11: 704–718, 1973.Google Scholar
  72. 72.
    Boucek RJ, Alvarez TR: Increase in survival of subcultured fibroblasts mediated by serotonin. Nature New Biology 229: 61–62, 1971.Google Scholar
  73. 73.
    Marguerie GA, Plow EF: The fibrinogen-dependent pathway of platelet aggregation. Ann NY Acad Sci 408: 556–566, 1983.Google Scholar
  74. 74.
    Nachman RL, Weksler B, Ferris B: Characterization of human platelet vascular permeability-enhancing activity. J Clin Invest 51: 549–555, 1972.Google Scholar
  75. 75.
    Wood S: Pathenogenesis of metastasis formation observed in vivo in the rabbit ear chamber. AMA Archives of Pathology 66: 550–568, 1958.Google Scholar
  76. 76.
    Niewiarowski S: Proteins secreted by the platelet. Thrombos Haemostas 38: 924–938, 1977.Google Scholar
  77. 77.
    Capitianio AM, Niewiaroswki S, Tuszynski CP, Kornecki E, Rao K: The interaction platelet factor X with human platelets and its association with the platelet tritium X-100 insoluble cytoskeleton (Abstract). Blood 60 (suppl): 709, 1982.Google Scholar
  78. 78.
    Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ: Antiheparin proteins secreted by human platelets: purification, characterization, and radioimmunoassay. Blood 53: 47–62, 1979.Google Scholar
  79. 79.
    Ross R, Vogel A: The platelet-derived growth factor. Cell 14: 203–210, 1978.Google Scholar
  80. 80.
    Cowan DH, Graham J: Stimulation of human tumor colony formation by platelet lysate. J Lab Clin Med 102: 973–986, 1983.Google Scholar
  81. 81.
    Stiles CD: The molecular biology of platelet-derived growth factor. Cell 33: 653–655, 1983.Google Scholar
  82. 82.
    Turner WA, Menter DG, Honn KV, Taylor JD: Tumor cell-induced fibronectin release. (Abstract) Proc Am Assoc Cancer Res 23: 97, 1983.Google Scholar
  83. 83.
    McKeown-Longo PJ, Hanning R, Mosher DF: Binding and degradation of platelet thrombospondin by cultured fibroblasts. J Cell Biol 98: 22–28, 1984.Google Scholar
  84. 84.
    Meyer D, Baumgartner HR: Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 54: 1–9, 1983.Google Scholar
  85. 85.
    Fujimotu T, O'Hara S, Hawiger J: Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest 69: 1212–1222, 1982.Google Scholar
  86. 86.
    Ruan C, Tobolem G, McMichael AJ, Drouet L, Legrand Y, Degos L, Kieffer N, Lee H, Caen JP: Monoclonal antibody to human platelet glycoprotein I: II. Effects of human platelet function. Br J Haematol 49: 511–519, 1981.Google Scholar
  87. 87.
    Tuszynski GP, Niewiarowski S, Lawley J, Srivastava S: Thrombospondin as a potential fibrin receptor on platelets identified by affinity chromatography. (Abstract) Circulation 68 (suppl III): 317, 1983.Google Scholar
  88. 88.
    Gogstad GO, Hagen I, Korsmo R, Solum NO: Evidence for a separate location of platelet glycoprotein II and III in the alpha granule membrane. (Abstract) Thromb Haemost 46: 109, 1981.Google Scholar
  89. 89.
    Wasteson A, Glimelius B, Busch D, Westermark B, Heldin C-H, Norling B: Effect of a platelet endoglycosidase on cell surface associated heparan sulphate of human cultured endothelial and glial cells. Thromb Res 11: 309–321, 1977.Google Scholar
  90. 90.
    Nakajima M, Irimura T, di Ferrante D, di Ferrante N, Nicolson G: Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220: 611–612, 1983.Google Scholar
  91. 91.
    Seamon KB, Padgett W, Daly JW: Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci 78: 3363–3367, 1981.Google Scholar
  92. 92.
    Mussoni L, Poggi A, de Gaetano G, Donati MB: Effect of Ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. Brit J Cancer 37: 126–129, 1978.Google Scholar
  93. 93.
    Jaffe BM, Santoro MG: Prostaglandins and cancer. Environ. Sci Res 29: 313–319, 1983.Google Scholar
  94. 94.
    Gasic G, Gasic T: Removal of sialic acid from the cell coat in tumor cells and vascular endothelium and its effects on metastasis. Proc Natl Acad Sci (USA) 48: 1172–1177, 1962.Google Scholar
  95. 95.
    Choi S-I, Simone JV, Journey LJ: Neuraminidase-induced thrombocytopenia in rats. Br J Haematol 22: 93–101, 1972.Google Scholar
  96. 96.
    Grottum KA, Jeremic M: Neuraminidase injections in rabbits: reduced platelet surface change, aggregation and thrombocytopenia. Thrombos Diathes Haemorrh 29: 461–469, 1973.Google Scholar
  97. 97.
    Greenburg J, Packham MA, Cazenave J-P, Reimers H-J, Mustard JF: Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 32: 476–484, 1975.Google Scholar
  98. 98.
    Gasic G, Gasic T, Stewart CC: Anti-metastatic effects associated with platelet reduction. Proc Natl Acad Sci (USA) 61: 46–52, 1968.Google Scholar
  99. 99.
    Morrison FS, Baldini MG: Antigenic relationship between blood platelets and vascular endothelium. Blood 33: 46–56, 1969.Google Scholar
  100. 100.
    Pearlstein E, Abrogio C, Karpatkin S: Lack of effect of PGI2 on the development of pulmonary metastases in mice following the intravenous injection of three syngeneic tumors; inhibition of metastases with anti-platelet antibody. (Abstract) Proceedings of the American Federation of Clinical Research, Washington DC, May 4–7, 1984.Google Scholar
  101. 101.
    Awouters F, Leysen JE, De Clerck F, van Nueten JM: General pharmacological profile of ketanserin (R41468), a selective 5-HT2 receptor antagonist. In: De Clerck F, Vanhoutte PM (eds) 5-Hydroxytryptamine in peripheral reactions. Raven Press, New York, 1982, pp 193–198.Google Scholar
  102. 102.
    Skolnik G, Ericsson LE, Bagge U: The effect of thrombocytopenia and anti-serotonin treatment on the lodgement of circulating tumor cells. J Cancer Res Clin Oncol 105: 30–37, 1983.Google Scholar
  103. 103.
    George JN, Thoi LL, McManus LM, Reimann TA: Isolation of human platelet membrane microparticles from plasma and serum. Blood 60: 834–840, 1982.Google Scholar
  104. 104.
    Gorelik E, Wiltrout RH, Brunda MJ, Holden HT, Herberman RB: Augmentation of metastasis formation by thyoglycollate-elicited macrophages. Int J Cancer 29: 575–581, 1982.Google Scholar
  105. 105.
    Gasic GJ, Gasic TB, Murphy S: Anti-metastatic effect of aspirin. Lancet 2: 713, 1972.Google Scholar
  106. 106.
    Wood S, Hilgard P: Aspirin and tumour metastasis. Lancet 2: 1416–1417, 1972.Google Scholar
  107. 107.
    Hilgard P, Schmidt CG: The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch 86: 243–250, 1976.Google Scholar
  108. 108.
    Honn KV, Cicone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Science 212: 1270–1272, 1981.Google Scholar
  109. 109.
    Menter DG, Onoda JM, Taylor JD, Honn KV: Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res 44: 450–456, 1984.Google Scholar
  110. 110.
    Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N: Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrocloride (ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. Cancer Res 41: 4710–4714, 1981.Google Scholar
  111. 111.
    Agarwal KC, Parks RE: Forskolin: a potential antimetastatic agent. Int J Cancer 32: 801–804, 1983.Google Scholar
  112. 112.
    Honn KV: Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Expl Metastasis 1: 103–114, 1983.Google Scholar
  113. 113.
    Honn KV, Busse WD, Sloane BF: Prostacyclin and thromboxanes: implications for their role in tumor cell metastasis. Biochemical Pharmacology 32: 1–11, 1983.Google Scholar
  114. 114.
    Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF: Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. In: Nicolson GL, Milas L (eds) Tumor invasion and metastasis. Raven Press, New York, 1984, pp 361–388.Google Scholar
  115. 115.
    Kolenich JJ, Mansour EG, Flynn A: Haematological effects of aspirin. Lancet 2: 714, 1972.Google Scholar
  116. 116.
    Atherton A, Busfield D, Hellmann K: The effects of an antimetastatic agent, (=)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane (ICRF 159), on platelet behavior. Cancer Res 35: 953–957, 1975.Google Scholar
  117. 117.
    Gordon S, Witul M, Cohen H, Sciandra J, Williams P, Gastpar H, Murphy GP, Ambrus JL: Studies of platelet aggregation inhibitors in vivo VIII; effect of pentoxifylline on spontaneous metastases. J Med 10: 435–441, 1979.Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1984

Authors and Affiliations

  • Gabriel J. Gasic
    • 1
  1. 1.Laboratory of Experimental Oncology, Section of Hematology and OncologyPennsylvania HospitalPhiladelphiaUSA
  2. 2.Laboratory of Experimental OncologyPennsylvania HospitalPhiladelphiaUSA

Personalised recommendations